Company Description
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States.
The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers.
The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders.
It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited.
Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | George Ng |
Contact Details
Address: 601 21st Street, Suite 300 Vero Beach, Florida 32960 United States | |
| Phone | 772 453 2899 |
| Website | processapharmaceuticals.com |
Stock Details
| Ticker Symbol | PCSA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1533743 |
| CUSIP Number | 74275C403 |
| ISIN Number | US74275C4033 |
| Employer ID | 45-1539785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| George K. Ng Esq., J.D. | Chief Executive Officer and Director |
| Russell L. Skibsted M.B.A. | Chief Financial Officer |
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, President of Research and Development and Director |
| Patrick Lin | Co-Founder, Chief Business and Strategy Officer |
| Wendy J. Guy | Co-Founder, Chief Administrative Officer and Corporate Secretary |
| Dr. Steven Cha M.D. | Senior Vice President of Clinical Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 5, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 5, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 5, 2026 | 8-K | Current Report |
| Nov 4, 2026 | 8-K | Current Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 23, 2026 | EFFECT | Notice of Effectiveness |
| Oct 22, 2026 | DEF 14A | Other definitive proxy statements |
| Oct 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |